Mechanism contrast
Tranexamic acid is a synthetic derivative of lysine. Topically, it inhibits the plasminogen-plasmin pathway in keratinocytes and reduces melanocyte activation in response to UV and inflammation. This is the only major topical that targets the inflammation-pigment axis directly, which is why it dominates the modern melasma protocol.
Alpha-arbutin is a glycosylated form of hydroquinone. The glucose protects the molecule and slows its hydrolysis, so the parent compound never reaches a cytotoxic dose. It binds tyrosinase reversibly, blocking the rate-limiting step of new melanin production at the source.
Evidence summary
Kim et al. (Acta Derm Venereol 2017) showed 5% topical tranexamic acid matched 4% hydroquinone in a 12-week melasma trial, with fewer adverse events. Polnikorn (J Cosmet Laser Ther 2010) reported visible lightening of melasma after 12 weeks of 1% alpha-arbutin. The two studies underpin the modern combination protocol: pair tranexamic acid for the hormonal-melasma cascade with alpha-arbutin for everyday tyrosinase suppression.
BIOSAR products that contain each
Tranexamic acid is the lead active in the Serenvit Tranexamic Acid Serum. It pairs in the routine with niacinamide AM/PM and vitamin C in the morning.
Alpha-arbutin sits inside the Whitepurity Serum and the Serenvit Vitamin Complex Serum. It is the brightening base for everyday tone-evening, while the Serenvit tranexamic acid serum is reserved for stubborn melasma.
Closing recommendation
Treat tranexamic acid as the targeted melasma player. Treat alpha-arbutin as the everyday brightener that fits any routine. The most stubborn pigmentation cases use both, ideally with niacinamide as the base and vitamin C in the morning. Sunscreen is non-negotiable for any pigment-fading protocol; without it the result plateaus.